Glucagon-like peptide-1:: a major regulator of pancreatic β-cell function

被引:106
作者
Perfetti, R
Merkel, P
机构
[1] Cedars Sinai Med Ctr, Dept Med, Div Endocrinol & Metab, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
关键词
D O I
10.1530/eje.0.1430717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide-1 (GLP-1) is a gut hormone synthesized by post-translational processing in intestinal L-cells, and it is released in response to food ingestion. GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pm)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion. GLP-1 has also been shown to have a prosatiety effect. In addition, it has been demonstrated that a long-term infusion with GLP-1, or exendin-4, a long-acting analog of human GLP-1, increases beta -cell mass in rats. In conclusion, GLP-1 appears to regulate plasma glucose levels via various and independent mechanisms. GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.
引用
收藏
页码:717 / 725
页数:9
相关论文
共 55 条
  • [1] Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
    Ahren, B
    Larsson, H
    Holst, JJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 473 - 478
  • [2] *AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS1
  • [3] Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients
    Creutzfeldt, WOC
    Orskov, C
    Kleine, N
    Holst, JJ
    Willms, B
    Nauck, MA
    [J]. DIABETES CARE, 1996, 19 (06) : 580 - 586
  • [4] DALESSIO D, 1997, DIABETES S1, V46, pA29
  • [5] GLUCAGON-LIKE PEPTIDE-1 ENHANCES GLUCOSE-TOLERANCE BOTH BY STIMULATION OF INSULIN RELEASE AND BY INCREASING INSULIN-INDEPENDENT GLUCOSE DISPOSAL
    DALESSIO, DA
    KAHN, SE
    LEUSNER, CR
    ENSINCK, JW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) : 2263 - 2266
  • [6] ENTERAL ENHANCEMENT OF GLUCOSE DISPOSITION BY BOTH INSULIN-DEPENDENT AND INSULIN-INDEPENDENT PROCESSES - A PHYSIOLOGICAL-ROLE OF GLUCAGON-LIKE PEPTIDE-I
    DALESSIO, DA
    PRIGEON, RL
    ENSINCK, JW
    [J]. DIABETES, 1995, 44 (12) : 1433 - 1437
  • [7] HUMAN ISLETS CHRONICALLY EXPOSED INVITRO TO DIFFERENT STIMULI BECOME UNRESPONSIVE TO THE SAME STIMULI GIVEN ACUTELY - EVIDENCE SUPPORTING SPECIFIC DESENSITIZATION RATHER THAN BETA-CELL EXHAUSTION
    DAVALLI, AM
    PONTIROLI, AE
    SOCCI, C
    BERTUZZI, F
    FATTOR, B
    BRAGHI, S
    DICARLO, V
    POZZA, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (04) : 790 - 794
  • [8] GLUCAGON-LIKE PEPTIDE-I REDUCES POSTPRANDIAL GLYCEMIC EXCURSIONS IN IDDM
    DUPRE, J
    BEHME, MT
    HRAMIAK, IM
    MCFARLANE, P
    WILLIAMSON, MP
    ZABEL, P
    MCDONALD, TJ
    [J]. DIABETES, 1995, 44 (06) : 626 - 630
  • [9] GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) ENHANCES INSULIN-STIMULATED GLUCOSE-METABOLISM IN 3T3-L1 ADIPOCYTES - ONE OF SEVERAL POTENTIAL EXTRAPANCREATIC SITES OF GLP-1 ACTION
    EGAN, JM
    MONTROSERAFIZADEH, C
    WANG, YH
    BERNIER, M
    ROTH, J
    [J]. ENDOCRINOLOGY, 1994, 135 (05) : 2070 - 2075
  • [10] THE INSULINOTROPIC ACTIONS OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) AND GLUCAGON-LIKE PEPTIDE-1(7-37) IN NORMAL AND DIABETIC SUBJECTS
    ELAHI, D
    MCALOONDYKE, M
    FUKAGAWA, NK
    MENEILLY, GS
    SCLATER, AL
    MINAKER, KL
    HABENER, JF
    ANDERSEN, DK
    [J]. REGULATORY PEPTIDES, 1994, 51 (01) : 63 - 74